EUVIMEDEUVIMED entdecken
Crossref

Duration of monitoring for withdrawal in neonates exposed to in-utero opioids

Ayda Soltanian Tiranchi, Dina El Metwally iD, Katrina Mark iD

Journal of Neonatal-Perinatal Medicine · 2026

DOI: 10.1177/19345798251365202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neonatal-Perinatal Medicine, 2026. Verfasst von Ayda Soltanian Tiranchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Neonatal Abstinence Syndrome, Analgesics, Opioid, Prenatal Exposure Delayed Effects. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to determine the duration of NOWS symptom onset that leads to pharmacologic intervention in order to inform hospital discharge protocols and provide better guidance for patients. Patients and methods A retrospective chart review was conducted evaluating neonates with documented NOWS monitoring at the University of Maryland Medical Center from January 2017 to November 2022. Infants at 36 weeks gestation and above who were exposed to opioids in-utero were included. Paired maternal and neonatal charts were reviewed. Medical history, drug screen results, and time lapse from day of birth to the day of initiation of treatment were documented.

Results

Of 357 neonates monitored for NOWS, 215 (60.5%) received pharmacologic treatment. All neonates requiring treatment were identified by day of life (DOL) 5. Neonates exposed to multiple opioids were at the highest risk of requiring treatment. When compared to buprenorphine exposure, those exposed to oxycodone and multiple opioids were more likely to need treatment on DOL 0, while methadone-exposed neonates were more likely to require treatment on DOL 1 and 2.

Conclusions

This study provides valuable information for risk-stratification and safe discharge planning for neonates at risk for NOWS. The findings suggest that a 5-day monitoring period may be sufficient to identify neonates requiring pharmacologic treatment for NOWS, potentially allowing for earlier discharge in some cases. However, the timing of symptom onset varies based on the type of opioid exposure, highlighting the need for individualized care and anticipatory guidance for families.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal Abstinence SyndromeAnalgesics, OpioidPrenatal Exposure Delayed EffectsHumansInfant, NewbornFemaleRetrospective StudiesMalePregnancyMarylandTime FactorsMethadonePatient DischargeBuprenorphine

Stichwörter der Autor:innen

neonatal opioid withdrawalopioids

Substanzen

Analgesics, OpioidMethadoneBuprenorphine

Autor:innen und Institutionen

  • University of Maryland School of Medicine, Baltimore, MD, USA.

ORCID-Profile: Dina El Metwally, Katrina Mark

Zitieren

APA

Soltanian Tiranchi, A., Metwally, D. E., & Mark, K. (2026). Duration of monitoring for withdrawal in neonates exposed to in-utero opioids. Journal of Neonatal-Perinatal Medicine. https://doi.org/10.1177/19345798251365202

Vancouver

Soltanian Tiranchi A, Metwally DE, Mark K. Duration of monitoring for withdrawal in neonates exposed to in-utero opioids. Journal of Neonatal-Perinatal Medicine. 2026. doi:10.1177/19345798251365202

BibTeX
@article{SoltanianTiranchi2026,
  author = {Soltanian Tiranchi, Ayda and Metwally, Dina El and Mark, Katrina},
  title = {Duration of monitoring for withdrawal in neonates exposed to in-utero opioids},
  journal = {Journal of Neonatal-Perinatal Medicine},
  year = {2026},
  doi = {10.1177/19345798251365202}
}
Kostenlos starten →